stocks logo

NPCE Valuation

Neuropace Inc
$
9.360
+0.22(2.407%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

NPCE Relative Valuation

NPCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NPCE is overvalued; if below, it's undervalued.
AI Stock Picker

Historical Valuation

Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 3.06 is considered Fairly compared with the five-year average of -8.28. The fair price of Neuropace Inc (NPCE) is between 5.75 to 19.12 according to relative valuation methord.
Relative Value
Fair Zone
5.75-19.12
Current Price:9.38
Fair
-12.49
PE
1Y
3Y
5Y
Trailing
Forward
-26.71
EV/EBITDA
Neuropace Inc. (NPCE) has a current EV/EBITDA of -26.71. The 5-year average EV/EBITDA is -12.72. The thresholds are as follows: Strongly Undervalued below -34.27, Undervalued between -34.27 and -23.49, Fairly Valued between -1.94 and -23.49, Overvalued between -1.94 and 8.83, and Strongly Overvalued above 8.83. The current Forward EV/EBITDA of -26.71 falls within the Undervalued range.
-16.00
EV/EBIT
Neuropace Inc. (NPCE) has a current EV/EBIT of -16.00. The 5-year average EV/EBIT is -10.26. The thresholds are as follows: Strongly Undervalued below -27.93, Undervalued between -27.93 and -19.09, Fairly Valued between -1.42 and -19.09, Overvalued between -1.42 and 7.41, and Strongly Overvalued above 7.41. The current Forward EV/EBIT of -16.00 falls within the Historic Trend Line -Fairly Valued range.
3.06
PS
Neuropace Inc. (NPCE) has a current PS of 3.06. The 5-year average PS is 4.11. The thresholds are as follows: Strongly Undervalued below -1.33, Undervalued between -1.33 and 1.39, Fairly Valued between 6.84 and 1.39, Overvalued between 6.84 and 9.56, and Strongly Overvalued above 9.56. The current Forward PS of 3.06 falls within the Historic Trend Line -Fairly Valued range.
-24.24
P/OCF
Neuropace Inc. (NPCE) has a current P/OCF of -24.24. The 5-year average P/OCF is -11.52. The thresholds are as follows: Strongly Undervalued below -26.63, Undervalued between -26.63 and -19.08, Fairly Valued between -3.97 and -19.08, Overvalued between -3.97 and 3.58, and Strongly Overvalued above 3.58. The current Forward P/OCF of -24.24 falls within the Undervalued range.
-21.49
P/FCF
Neuropace Inc. (NPCE) has a current P/FCF of -21.49. The 5-year average P/FCF is -11.35. The thresholds are as follows: Strongly Undervalued below -27.03, Undervalued between -27.03 and -19.19, Fairly Valued between -3.51 and -19.19, Overvalued between -3.51 and 4.33, and Strongly Overvalued above 4.33. The current Forward P/FCF of -21.49 falls within the Undervalued range.
Neuropace Inc (NPCE) has a current Price-to-Book (P/B) ratio of 15.54. Compared to its 3-year average P/B ratio of 15.93 , the current P/B ratio is approximately -2.47% higher. Relative to its 5-year average P/B ratio of 11.82, the current P/B ratio is about 31.48% higher. Neuropace Inc (NPCE) has a Forward Free Cash Flow (FCF) yield of approximately -5.43%. Compared to its 3-year average FCF yield of -20.02%, the current FCF yield is approximately -72.89% lower. Relative to its 5-year average FCF yield of -17.49% , the current FCF yield is about -68.97% lower.
15.54
P/B
Median3y
15.93
Median5y
11.82
-5.43
FCF Yield
Median3y
-20.02
Median5y
-17.49
Intellectia AI SwingMax

Competitors Valuation Multiple

The average P/S ratio for NPCE's competitors is 3.31, providing a benchmark for relative valuation. Neuropace Inc Corp (NPCE) exhibits a P/S ratio of 3.06, which is -7.71% above the industry average. Given its robust revenue growth of 22.14%, this premium appears sustainable.
Financial AI Agent

Performance Decomposition

1Y
3Y
5Y
Market capitalization of NPCE increased by 31.13% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 19.26M to 23.52M.
The secondary factor is the P/E Change, contributed 14.73%to the performance.
Overall, the performance of NPCE in the past 1 year is driven by Revenue Growth. Which is more sustainable.
22.14%
19.26M → 23.52M
Revenue Growth
+
-5.74%
-39.02 → -36.78
Margin Expansion
+
14.73%
-9.50 → -10.90
P/E Change
=
31.13%
6.97 → 9.14
Mkt Cap Growth

FAQ

arrow icon

Is Neuropace Inc (NPCE) currently overvalued or undervalued?

Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 3.06 is considered Fairly compared with the five-year average of -8.28. The fair price of Neuropace Inc (NPCE) is between 5.75 to 19.12 according to relative valuation methord.
arrow icon

What is Neuropace Inc (NPCE) fair value?

arrow icon

How does NPCE's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Neuropace Inc (NPCE) as of Sep 03 2025?

arrow icon

What is the current FCF Yield for Neuropace Inc (NPCE) as of Sep 03 2025?

arrow icon

What is the current Forward P/E ratio for Neuropace Inc (NPCE) as of Sep 03 2025?

arrow icon

What is the current Forward P/S ratio for Neuropace Inc (NPCE) as of Sep 03 2025?